The Danish Maritime and Commercial Court ruled in favor of Danisco’s ownership of the innovation behind two Danisco amylase patent applications (EP2859097 and EP2825643). The court reasoned that Novozymes’ legal argument that an entitlement action could be based on prior art was without merit and awarded costs to Danisco.
“Testimony from the trial clearly showed that the inventions claimed in these patent applications were based on Danisco technology and reflect our long history of innovation throughout the globe,” said Wayne Ashton, Global Business Director for home and personal care at DuPont.
DuPont™ Danisco® is the brand for a range of products that help provide enhanced bioprotection, an improved nutritional profile, and better taste and texture with greater cost efficiency and lower environmental impact, meeting the needs of manufacturers of food and beverages and dietary supplements. Through the work of the global network of food scientists and technologists in DuPont, the Danisco® range is supported by a uniquely broad spectrum of know-how across applications and processing.
DuPont Nutrition & Biosciences applies expert science to advance market-driven, healthy and sustainable solutions for the food, beverage, dietary supplement and pharmaceutical industries. We also use cutting-edge biotechnology across a range of markets to advance bio-based solutions to meet the needs of a growing population, while protecting our environment for future generations. We are innovative solvers who help our customers turn challenges into high-value business opportunities.
DuPont (NYSE: DD) is a global innovation leader with technology-based materials, ingredients and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, health and wellness, food and worker safety. More information can be found at www.dupont.com/